These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 10602522)
1. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Loging WT; Reisman D Oncogene; 1999 Dec; 18(52):7608-15. PubMed ID: 10602522 [TBL] [Abstract][Full Text] [Related]
2. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type. Thomas S; Reisman D Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433 [TBL] [Abstract][Full Text] [Related]
3. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53. Loging WT; Reisman D Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557 [TBL] [Abstract][Full Text] [Related]
4. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833 [TBL] [Abstract][Full Text] [Related]
5. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999 [TBL] [Abstract][Full Text] [Related]
6. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53. Cui XS; Donehower LA Oncogene; 2000 Dec; 19(52):5988-96. PubMed ID: 11146550 [TBL] [Abstract][Full Text] [Related]
7. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Ala-aho R; Grénman R; Seth P; Kähäri VM Oncogene; 2002 Feb; 21(8):1187-95. PubMed ID: 11850838 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Xu D; Wang Q; Gruber A; Björkholm M; Chen Z; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P Oncogene; 2000 Oct; 19(45):5123-33. PubMed ID: 11064449 [TBL] [Abstract][Full Text] [Related]
9. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells]. Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103 [TBL] [Abstract][Full Text] [Related]
10. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Inga A; Resnick MA Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991 [TBL] [Abstract][Full Text] [Related]
11. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705 [TBL] [Abstract][Full Text] [Related]
12. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250 [TBL] [Abstract][Full Text] [Related]
13. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139 [TBL] [Abstract][Full Text] [Related]
14. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Srivenugopal KS; Shou J; Mullapudi SR; Lang FF; Rao JS; Ali-Osman F Clin Cancer Res; 2001 May; 7(5):1398-409. PubMed ID: 11350911 [TBL] [Abstract][Full Text] [Related]
15. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Pugacheva EN; Ivanov AV; Kravchenko JE; Kopnin BP; Levine AJ; Chumakov PM Oncogene; 2002 Jul; 21(30):4595-600. PubMed ID: 12096336 [TBL] [Abstract][Full Text] [Related]
16. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Willis A; Jung EJ; Wakefield T; Chen X Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206 [TBL] [Abstract][Full Text] [Related]
17. Modulation of gene expression by tumor-derived p53 mutants. Scian MJ; Stagliano KE; Ellis MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S Cancer Res; 2004 Oct; 64(20):7447-54. PubMed ID: 15492269 [TBL] [Abstract][Full Text] [Related]
18. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Daoud SS; Munson PJ; Reinhold W; Young L; Prabhu VV; Yu Q; LaRose J; Kohn KW; Weinstein JN; Pommier Y Cancer Res; 2003 Jun; 63(11):2782-93. PubMed ID: 12782583 [TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Wesierska-Gadek J; Schmid G Cell Mol Biol Lett; 2001; 6(2):117-40. PubMed ID: 11544635 [TBL] [Abstract][Full Text] [Related]
20. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]